Publications by authors named "M E Connor"
Background: Amidst the difficulty and contentiousness of improving hospitals, a relatively new approach is the Relational Model of Organizational Change (RMOC). However, this approach has its own challenges, including reports that its focus on communication and relationships is undervalued despite evidence supporting its use to facilitate practice improvements in hospitals. Research suggests power dynamics in hospitals influences how the RMOC is used, but the precise mechanisms through which this occurs have not been fully examined.
View Article and Find Full Text PDFBackground: Therapeutic plasma exchange (TPE) is the primary intervention for treating symptomatic hyperviscosity from hypergammaglobulinemia, yet its efficacy for treating hyperviscosity related to hyperfibrinogenemia is unclear.
Objective: Define the safety and efficacy of TPE for critically ill COVID-19 patients with elevated blood viscosity from hyperfibrinogenemia.
Method: A prospective, randomized controlled trial in critically ill COVID-19 patients at a single US healthcare system.
Article Synopsis
- Radical prostatectomy (RP) is a key surgical treatment for prostate cancer, but assessing surgical margins during the procedure is difficult and costly, making fluorescence confocal microscopy (FCM) a potential solution.
- The IP8-FLUORESCE study is a multicentre, prospective study that investigates the accuracy of digital FCM in identifying prostate cancer at surgical margins, comparing it to traditional histopathology methods.
- The study will involve 153 patients undergoing robot-assisted RP, using FCM on prostate specimens immediately after surgery, with results evaluated by blinded uro-pathologists for accuracy in detecting cancer presence at the margins.
During maceration, a string of beads was found near the surgically modified right os coxa and femur of the remains of a 55-year-old woman donated to the Forensic Investigation Research Station at Colorado Mesa University. The remains were initially used in the study of decomposition of human remains, and then macerated to clean the skeleton. Documentation on this decedent noted three separate "hip replacement" surgeries, but no other details.
View Article and Find Full Text PDFPurpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy.
Methods: We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial.